Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease

Medical Science Monitor

Volumn 19, Issue , 2013, Pages 954-959

  Bartnicki, Piotr ^a   Fijałkowski, Paweł ^a   Majczyk, Małgorzata ^a   Błaszczyk, Jan ^a   Banach, Maciej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anemia; Chronic kidney disease (CKD); Erythropoiesis stimulating agents; Oxidative stress

Indexed keywords

CATALASE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PREDIALYSIS; RENAL REPLACEMENT THERAPY;

CATALASE; ERYTHROCYTES; ERYTHROPOIETIN; FEMALE; GLUTATHIONE PEROXIDASE; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; POLYETHYLENE GLYCOLS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; SUPEROXIDE DISMUTASE;

EID: 84887388695     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.884024     Document Type: Article

References (46)

1. US Renal Data System, USRDS, Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, 2009
2. Gosmanova EO, Le N-A: Cardiovascular complications in CKD patients: role of oxidative stress. Card Res Practice, 2011; 2011: 1-8
3. Hu P, Wang J, Lu L, Qin YH: Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease. Med Sci Monit, 2011; 17(6), HY14-20
4. Liborio A, Uchia R, Aragao A et al: Importance of anemia in the chronic cardiorenal syndrome: effects on renal function after heart transplantation. Med Sci Monit, 2012, 18(10): 611-16
5. Cachoferio V, Goicochea M, de Vinuesa SG et al: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int, 2008; 111: S4-S9
6. Del Vecchio L, Locatelli F, Carini M: What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment and prevention. Sem Dial, 2011; 1: 56-64
7. Rysz J, Mikhailidis DP, Banach M: Oxidative stress and atherosclerosis in chronic kidney disease. Arch Med Sci, 2009; 5: S415-20
8. Massy ZA, Stenvinkel P, Drueke TB: The role of oxidative stress in chronic kidney disease. Sem Dial, 2009; 4: 405-8
9. Siems W, Carluccio F, Radenkovic S et al: Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res, 2005; 28: 295-301
10. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M et al: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radical Biol Med, 1996; 6: 845-53
11. Libetta C, Sepe V, Esposito P et al: Oxidative stress and inflammation: implications in uremia and hemodialysis. Clinical Biochem, 2011; 44: 1189-98
12. Yimaz MI, Saglam M, Caglar K et al: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis, 2006; 1: 42-50
13. Capusa C, Mircescu G: Oxidative stress, renal anemia and its therapies: is there a link? J Ren Nutr, 2010; 20 (5 Suppl.): S71-S76
14. Johnson DW, Forman C, Vesey DA: Novel renoprotective actions of erythropoietin: New uses for an old hormone. Nephrology, 2006; 11: 306-12
15. Bahlmann FH, Fliser D: Erythropoietin and renoprotection. Curr Opin Nephrol Hyp, 2009; 18: 15-20
16. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M: Antioxidative effects of erythropoietin. Kidney Int, 2007; 72: S10-15
17. Mimic-Oka J, Simic T, Djukanovic L: Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patients. Ren Fail, 2002; 24: 77-87
18. Sommerburg O, Grune T, Hampl H et al: Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients? Clin. Nephrol, 2000; 53: S23-29
19. Macdougall IC, Walker R, Provenzano R et al, and ARCTOS Investigators: C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol, 2008; 3: 337-47
20. Kessler M, Martinez-Castelao A, Siamopoulos KC et al: C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hem Int, 2010; 14: 233-39
21. Lahera V, Goicoechea M, de Vinuesa SG et al: Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol, 2006; 17: S174-77
22. Dasgupta A, Hussain S, Ahmad S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron, 1992; 60: 56-59
23. Taccone-Gallucci M, Giardini O, Lubrano R et al: Red blood cell lipid peroxidation in predialysis chronic renal failure. Clin Nephrol, 1987; 27: 238-41
24. Misra HP, Fridovich J: The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem, 1972; 247: 3170-73
25. Sedlak J, Lindsay A: Estimation of total protein bound and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem, 1968; 26: 192-205
26. Little C, O'Brien P: An intracellular GSH-peroxidase with a lipid peroxide substrate. Biophys Res Commun, 1968; 31: 145-50
27. Beers R, Sizer T: Spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem, 1952; 195: 133-40
28. Placer Z, Cushman L, Jonson B: Estimation of product of lipid peroxidation malondialdehyde in biochemical systems. Anal Bioch, 1966; 16: 359-64
29. Small DM, Coombes JS, Bennett N et al: Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology, 2012; 17: 311-21
30. Vaziri ND: Oxidative stress in uremia: nature, mechanisms and potential consequences. Semin Nephrol, 2004; 24: 469-73
31. Vaziri ND, Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif, 2011; 31: 189-96
32. Renke M, Knap N, Tylicki L et al: Atorvastatin attenuates oxidative stress in patients with chronic kidney disease. Med Sci Monit, 2010; 16(3): LE3
33. Hakim F, Pflueger A: Role of oxidative stress in diabetic kidney disease. Med Sci Monit, 2010; 16(2): RA37-48
34. Drueke TB, Massy ZA: Intravenous iron: how much is too much? J Am Soc Nephrol, 2005; 16: 2833-35
35. Sela S, Shurtz-Swirski R, Cohen-Mazor R et al: Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. Am J Soc Nephrol, 2005; 16: 2431-38
36. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J: Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol, 2008; 19: 593-99
37. Crawford A, Fasett RG, Coombes JS et al: Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease. Nephrol Dial Transplant, 2011; 26: 2806-13
38. Elahi MM, Kong YX, Matata BM: Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev, 2009; 2: 259-69
39. Tapolyai M, Kadomatsu S, Perera-Chong M: r. hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol, 2003; 4: 3
40. Nangaku M, Fliser D: Erythropoiesis-stimulating agents: past and future. Kidney Int, 2007; 72: S1-S3
41. Dang J, Jia R, Tu Y et al: Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother, 2010; 64: 681-85
42. Calo LA, Stanic L, Davis PA et al: Effect of epoetin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. Int Clin Pharmacol Ther, 2003; 41: 187-92
43. Siems W, Carluccio F, Radenkovic S et al: Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res, 2005; 28: 295-301
44. Mimic-Oka J, Simic T, Djukanowic L: Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patients. Ren Fail, 2002; 24: 77-87
45. Kowalczyk M, Banach M, Mikhailidis DP, Rysz J: Erythropoietin update 2011. Med Sci Monit, 2011, 17(11): RA240-47
46. Menne J, Park JK, Shushakova N et al: The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol, 2007; 18: 2046-53